CClinicalTrials.gg
RecruitingNCT07815145Updated Sep 15, 2026

Quadroiliac Plane Block Versus Transmuscular Quadratus Lumborum Block for Postoperative Analgesia After Total Hip Arthroplasty

An interventional study of Quadroiliac Plane Block and Transmuscular quadratus lumborum block in Quadroiliac Plane Block, Transmuscular Quadratus Lumborum Block and Postoperative Analgesia, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Tanta University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study aims to evaluate and compare the postoperative analgesic efficacy, opioid consumption, motor function preservation, and quality of recovery of ultrasound-guided Quadroiliac Plane Block (QIPB) versus transmuscular quadratus lumborum block (QLB) in patients undergoing THA under spinal anesthesia.

Read the detailed description

Total hip arthroplasty (THA) is a common orthopedic procedure for end-stage hip diseases such as osteoarthritis and avascular necrosis. It is highly effective in relieving pain and restoring function.

The quadratus lumborum block (QLB) is one such fascial plane technique. It provides analgesia through spread of local anesthetics within the thoracolumbar fascia. This allows potential involvement of lumbar plexus branches.

The Quadroiliac Plane Block (QIPB) is a newer regional technique for hip and pelvic surgery. It targets fascial planes near the iliac region to block sensory innervation of the hip. Early studies suggest it may provide effective postoperative analgesia.

02

Conditions studied

  • Quadroiliac Plane Block
  • Transmuscular Quadratus Lumborum Block
  • Postoperative Analgesia
  • Total Hip Arthroplasty
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 18-75 years.
  • Both sexes.
  • American Society of Anesthesiologists (ASA) classification I-III.
  • Scheduled for elective primary unilateral total hip arthroplasty under spinal anesthesia.

Exclusion criteria

Exclusion Criteria:

  • Allergy to local anesthetics.
  • Infection at the injection site.
  • Coagulopathy or bleeding disorders.
  • Neuromuscular disorders.
  • Chronic opioid use or dependence.
  • Body mass index (BMI) > 40 kg/m².
  • Severe cardiac, hepatic, renal, or respiratory dysfunction.
  • Contraindication to regional anesthesia.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Group QIP

    Patients will receive an ultrasound-guided Quadroiliac Plane Block (QIPB) using 20 mL of bupivacaine 0.25%.

    Drug: Quadroiliac Plane Block

  • Experimental
    Group QLB

    Patients will receive ultrasound-guided quadratus lumborum block (QLB) (transmuscular approach) using 20 mL of 0.25% bupivacaine.

    Drug: Transmuscular quadratus lumborum block

Interventions

  • DrugQuadroiliac Plane Block

    Patients will receive an ultrasound-guided Quadroiliac Plane Block (QIPB) using 20 mL of bupivacaine 0.25%.

  • DrugTransmuscular quadratus lumborum block

    Patients will receive ultrasound-guided quadratus lumborum block (QLB) (transmuscular approach) using 20 mL of 0.25% bupivacaine.

05

What researchers measure

Primary outcomes

  1. Total morphine consumption

    Rescue analgesia of morphine will be given as 3 mg bolus if the numeric rating scale (NRS) \> 3 to be repeated after 30 min if pain persists until the NRS \< 4.

    Time frame: 24 hours postoperatively

Secondary outcomes

  1. Degree of pain

    Each patient will be instructed about postoperative pain assessment with the numeric rating scale (NRS) score. NRS (0 represents "no pain" while 10 represents "the worst pain imaginable"). NRS will be assessed at post-anesthesia care unit (PACU), 2, 4, 6, 12, and 24 h postoperatively.

    Time frame: 24 hours postoperatively

  2. Time to the 1st rescue analgesia

    Time to the first request for rescue analgesia will be recorded from the end of block to first dose of morphine administrated.

    Time frame: 24 hours postoperatively

  3. Time for ambulation

    Time to ambulation: the time interval (in hours) from the end of surgery to the first successful mobilization of the patient, defined as the ability to stand and walk at least 3-5 steps with or without assistance.

    Time frame: 24 hours postoperatively

  4. Length of hospital stay

    Length of hospital stay will be recorded from admission till the discharge from hospital.

    Time frame: Till the discharge from hospital (Up to 2 weeks)

  5. Incidence of adverse events

    Incidence of adverse events such as bradycardia, hypotension, nausea, vomiting, respiratory depression, or any other complication will be recorded.

    Time frame: 24 hours postoperatively

06

Study locations

1 of 1 sites recruiting
07

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07815145
Lead sponsor
Tanta University
Responsible party
Mohammed Said ElSharkawy (Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt., Tanta University) — Principal investigator
First posted
Sep 11, 2026
Start date
Sep 12, 2026
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Sep 15, 2026

Study contacts

Mohammed S Elsharkawy, MD
Contact
mselsharkawy@med.tanta.edu.eg
00201148207870

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion